#United States #San Francisco #Immorta Bio #SenoVax #StemCell Revivify

Immorta Bio's Innovations for a Healthier Future

Immorta Bio Inc., a frontrunner in biotechnologies aimed at enhancing longevity, is set to reveal exciting developments at the upcoming Biotech Showcase 2025 on January 14, held at the Franciscan Ballroom in San Francisco. Dr. Thomas Ichim, President and Chief Scientific Officer, will lead the discussion, revealing deep insights into the company's innovative platforms that focus on treating diseases associated with aging.

Focus on Senolytic Medicine

One of the highlights of the presentation will be SenoVax™, a novel dendritic cell-based vaccine designed to target senescent cells, which are known to accumulate as we age. These cells are linked to various aging-related diseases and contribute to the deterioration of the immune system. Preclinical studies have shown promising results, indicating that SenoVax™ can not only eliminate these detrimental cells but also rejuvenate the tumor microenvironment, offering a new approach to cancer treatment. In animal models involving multiple types of solid tumors, such as lung and breast cancers, SenoVax™ has demonstrated a marked regression, significantly boosting immune responses against tumors.

StemCell Revivify™: Pioneering Cellular Health

In addition to SenoVax™, Immorta Bio will discuss StemCell Revivify™, which encompasses a unique collection of personalized young and immortal progenitor and mesenchymal stem cells. These advanced cellular therapies have shown the capability to rejuvenate failing organs, restoring function in animal models. By utilizing proprietary iPSC-based stem cell technologies, the company aims to provide scalable and cost-effective treatment options that enhance organ recovery and combat age-related health challenges.

Addressing Aging as a Disease

Dr. Ichim emphasizes the importance of viewing aging itself as a disease that can be treated. "At Immorta Bio, our mission is clear: we aim to revolutionize how medical challenges related to aging are approached, combining advanced science with a comprehensive understanding of biological aging processes,” he states excitedly. With the insights shared at Biotech Showcase, Immorta Bio aspires to foster collaboration with other innovators and engage investors interested in sustainability and longevity medicine.

Join the Conversation

The Biotech Showcase is an invaluable opportunity for stakeholders in the biotechnology field to explore innovative solutions aimed at health and longevity. To learn more about this landmark event, visit Biotech Showcase. For those interested, scheduling a one-on-one meeting with Dr. Thomas Ichim during the showcase can be done by reaching out at [email protected].

About Immorta Bio

Founded with a singular purpose, Immorta Bio Inc. is dedicated to developing cellular therapeutics that address diseases of aging. The company's focus on optimizing stem cells and enhancing immune responses positions them at the forefront of longevity research, aiming to restore health and vitality in aging populations. For further details on their studies and breakthroughs, visit their website at immortabio.com and follow them on social media.

Conclusion

As the quest for longevity solutions advances, Immorta Bio continues to pave the way, highlighting the crucial intersection of science, health, and the human experience. The upcoming Biotech Showcase promises to showcase not only the potential of Immorta Bio’s innovative therapies but also sparks the dialogue necessary for transformative change in how we perceive and combat aging.